₹15,331 Cr
28.96
₹529 Cr
As on 13-Aug-2024 IST
₹-87.65
•
-1.30%
₹6,736.85
₹6,750.00
₹6,774.65
₹6,625.10
6,286
₹5,892.80 - 10,524.95
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Sanofi India
| -17.58 | 4.26 | -16.46 | -6.67 | -9.01 | 1.47 | 8.10 |
|
BSE Healthcare
| 30.05 | 6.86 | 18.26 | 46.79 | 16.31 | 26.45 | 12.81 |
|
BSE Mid Cap
| 26.89 | -1.61 | 13.94 | 53.62 | 26.75 | 27.88 | 17.84 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Sanofi India
| 37.83 | -25.79 | -4.64 | 18.71 | 10.51 | 35.57 | 10.22 |
|
BSE Mid Cap
| 45.53 | 1.38 | 39.18 | 19.87 | -3.05 | -13.31 | 48.13 |
|
BSE Healthcare
| 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 | 0.49 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Sanofi India Ltd stood at ₹ 1,360 Cr as on 30-Jun-24
The share price of Sanofi India Ltd is ₹6,649.20 (NSE) and ₹6,656.95 (BSE) as of 13-Aug-2024 IST. Sanofi India Ltd has given a return of -9.01% in the last 3 years.
Sanofi India Ltd has a market capitalisation of ₹ 15,331 Cr as on 13-Aug-2024. As per Value Research classification, it is a Mid Cap company.
The P/B ratio of Sanofi India Ltd is 22.39 times as on 13-Aug-2024, a 268% premium to its peers’ median range of 6.09 times.
The P/E ratio of Sanofi India Ltd is 28.96 times as on 13-Aug-2024, a 32% discount to its peers’ median range of 42.30 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Sanofi India Ltd and enter the required number of quantities and click on buy to purchase the shares of Sanofi India Ltd.
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, infections, central nervous system, anti-infectives, epilepsy, allergy and vitamins, and minerals and supplements, as well as pain care and nutritional health under the Lantus, Toujeo, Clexane, Amaryl, Cardace, Glimepiride, Cetapin, Targocid, Frisium, Combiflam, DePura, Allegra, and Avil brands through independent distributors. It also exports its products to approximately 35 countries. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.
The promoter of Sanofi India Ltd is Hoechst Gmbh. Hoechst Gmbh owns 60.37 per cent of the total equity. The chairman of the company is Aditya Narayan , and the managing director is Rodolfo Hrosz..
There is no promoter pledging in Sanofi India Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
57,836
|
|
|
48,762
|
|
|
40,418
|
|
|
37,484
|
| Sanofi India Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
62.95
|
|
Operating margin(%)
|
26.54
|
|
Net Margin(%)
|
18.73
|
|
Dividend yield(%)
|
2.51
|
Yes, TTM profit after tax of Sanofi India Ltd was ₹529 Cr.
₹15,331.37 Cr
₹2,604.40 Cr
₹529.40 Cr
₹260.20 Cr
₹0.00 Cr
60.40%
High
₹5,892.80 - 10,524.95
₹10.00
2,30,30,622
BSE: 500674, NSE: SANOFI
Mumbai, Maharashtra
www.sanofiindialtd.com
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis,... infections, central nervous system, anti-infectives, epilepsy, allergy and vitamins, and minerals and supplements, as well as pain care and nutritional health under the Lantus, Toujeo, Clexane, Amaryl, Cardace, Glimepiride, Cetapin, Targocid, Frisium, Combiflam, DePura, Allegra, and Avil brands through independent distributors. It also exports its products to approximately 35 countries. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH. Read more
Stocks 
Sanofi India Ltd.
Widely used:
